Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2006-11-14
2006-11-14
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S184100, C424S190100, C424S192100, C424S193100, C424S200100, C424S207100, C424S210100, C424S234100, C424S237100, C514S002600
Reexamination Certificate
active
07135188
ABSTRACT:
Methods and vaccines for suppressing formation of or inhibiting growth of tumors in a host are provided, via administration of a vaccine containing either a fusion protein of the tumor associated antigen fused to a truncated form of listeriolysin or a recombinant form ofListeria monocytogeneswhich grows and spreads and is capable of expressing the tumor associated antigen alone or as a listeriolysin fusion protein.
REFERENCES:
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6565852 (2003-05-01), Paterson
patent: 6767542 (2004-07-01), Paterson et al.
patent: 6855320 (2005-02-01), Paterson
patent: 2003/0028206 (2003-02-01), Shiber
patent: 2003/0202985 (2003-10-01), Paterson
patent: 2005/0118184 (2005-06-01), Paterson et al.
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: 2006/0051380 (2006-03-01), Schulick et al.
patent: 2006/0093582 (2006-05-01), Paterson et al.
patent: 2006/0121053 (2006-06-01), Sweeney et al.
patent: WO 96/14087 (1996-05-01), None
patent: WO 99/10496 (1999-04-01), None
patent: WO 99/06544 (1999-11-01), None
patent: WO 01/27295 (2001-04-01), None
patent: WO 01/72329 (2001-10-01), None
Mandal et al, BBA, 2002, 1563:7-17.
Kerksiek et al, Current Opinion in Immunology, 1999, 11:400-405.
Harty et al, Current Opinion in Immunology, 1996, 8:526-530.
Shen et al, Current Opinion in Immunology, 1998, 10:450-458.
Paterson et al, Current Opinion in Immunology, 1996, 8:664-669.
Lara-Tejero et al, Current Opinion in Microbiology, 2004, 7:45-50.
Gunn, Dissertation Abstracts International, 2001, 62/5B:2244 Abstract only.
Beatty, Dissertation Abstracts International, 2000, 61/10B:5224 Abstract only.
Gunn et al, J. Immunology, 2001, 167:6471-6479.
Hu et al, J. Immunology, 2004, 172:1595-1601.
Burnham, Drug Discovery Today, Jan. 2003, 8/2:54-55.
Pan et al, Cancer Research, 1999, 59:5264-5269.
Lamikanra et al, J. Virology, Oct. 2001, 75/20:9654-9664.
Ikonomidis et al, J. Exp. Med., Dec. 1994, 180:2209-2218.
Radford et al, GeneTherapy, 2002, 9:1455-1463.
Radford et al, Int. J. Cancer, 2003, 105:811-819.
Gunn et al, TRENDS in Microbiology, Apr. 2001, 9/4:161-162.
Peng et al, J. Immunology, 2004, 172:6030-6038.
Dermime et al, BBA, 2004, 1704:11-35.
Penichet et al, J. Immunological Methods, 2001, 248:91-101.
Cunto-Amesty et al, International J Parasitology, 2003, 33:597-613.
Roden et al, Human Pathology, 2004, 35:971-982.
Bruhn et al, Vaccine, 2005, Article in Press, 10 pages.
Cheever M, et al, “T-Cell Immunity to Oncogenic Proteins Including Mutaed RAS and Chimeric BCR-ABL”, Annual New York Academy of Science.
Camilli A, et al. “Dual roles of plcA in Lesteria monocytogenes pathogenesis” molecular Microbiology (1993) 8(1), 143-157.
Boon et al “Tumor Antigens Recognized by T Lymphocytes” Annu. Rev. Immunol, 1994, 12:337-65.
Weiskirch L. M. et al “Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease” immunological Reviews 1997, vol. 158:159-169.
Zhang S et al. “Selection of Tumor Antigens as Targets for Immune Attach Using Immunohistochemistry: Protein Antigens” Clinical Cancer Research, vol. 4, 2669-2676, 1998.
Stover C.K. et al., “New use of BCG for recombinant vaccines” Nature, vol. 351, 1991.
Townsend S.E. et al., “Tumor Rejection After Direct Constimulation of CD8+ T Cells by B7-Transfected Melanoma Cells” Science, vol. 259, 1993, 368-370.
McCarty T. M. et al., “Targeting p53 for Adoptive T-Cell Immunotheraphy” Cancer Research 58, 2601-2605 1981.
McKaig R. G. et al., “Human Papillomavirus and Head and Neck Cancer: Epidemiology and Molecular Biology”, Basic Science Review, 1998, 20(3): 250-265.
Pagano Joseph S. “Epstein-Barr Virus: The First Human Tumor Virus and its Role in Cancer” Proceedings of the Association of American Physicians, vol. III , No. 6 pp. 573-580, 1999.
Punwaney R et al “Human Papillomavirus may be Common within Nasopharyngeal Carcinoma of Causcasian Americans: Investigation of Epstein-Barr Virus and Human Palillomavirus in Eastern and Western Nasopharyngeal Carcinoma using Litigation-Dependent Polymerase Chain Reaction” 1999, Head Neck, 21/1: 21-29.
Schafer R. et al., “Induction of a Cellular Immune Response to a Foreign Antigen by a Recombinant Listria monocytogenes Vaccine” The Journal of Immunology, vol. 149, 53-59, No. 1, 1992.
Serth J. et al., “Increased Levels of Human Papillomavirus Type 16 DNA in a Subset of Prostrate Cancer” Cancer Research 59, 823-825, 1999.
Finn D.J. et al., ,MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines Immunological Review, No. 145, 1995, 61-89.
Gillespie A. M. et al., “The potential of melanoma antigen expression in cancer therapy” Cancer Treatment Reviews, 25: 219-227, 1999.
Golumbek P.T. et al., “Treatment of Establishment Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4” Science vol. 254, 1991, 713-716.
Kawashima I, et al., “The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors” human Immunology 59, 1-14, 1998.
In Vivo Depletion of CD4- and CD8-specific T cells, Current Protocols in Immunology 4.1.1-4.1.5, 1991.
Travis, J., “A Stimulating New Approach to Cancer Treatment”. Science. 1993, 259, 310-311.
Wirth, R , F.Y An and D B Clewell, “Highly Efficient Protoplast Transformation System forStreptococcus Faecalisand a NewEscherichia Coli-S. FaecalisShuttle Vector”, J Bacteriol , 1986, 165, 831-836.
Ikonomidis, et al, “Recombinant Listeria Monocytogenes Cancer Vaccines”, Vaccines, 95, 1995, 95:317-326.
Paterson, et al, Proceedings of the American Association for Cancer Research, Mar. 2000, 41:890, Abstract#s25.
Pan, et al, Cancer Research, Nov. 1, 1995, vol. 55: 4776-4779.
Aggarwal et al , “Oral Salmonella: Malaria Circumsporozoite Recombinants Induce Specific CD8+Cytotoxic T Cells”, J of Exp Med , 1990, 172, 1083-1090.
Cheever et al , “T-Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR-ABL”, Annals N Y Acad Sci , 1993, 690:101-112.
Disis et al , “Immunity to the HER-2
eu Oncogenic Protein”, Ciba Found Symp , 1994, 187:198-211.
Gansbacher et al, “Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity”, J Exp Med , 1990, 172, 1217-1224.
A Kruisbeek, Current Protocols in Immunology, Coligan et al , eds. John Wiley & Sons, Inc , 1994. V.1, 4 1.1-4 1 2.
Restifo et al., “Identification of Human Cancers Deficient in Antigen Processing”, J of Exp Med , 1993. 177, 265-272.
Stover et al , “New Use of BCG for Recombinant Vaccines”, Nature, 1991, 351, 456-460.
Sun et al., “Isolation of Listeria Monocytogenes Small-Plaque Mutants Defective for Intracellular Growth and Cell-to-Cell Spread”, Infection and Immunity, 1990, 58, 3770-3778.
Tilney, L G. and D A Portnoy. “Actin Filaments and the Growth, Movement. and Spread of the Intracellular Bacterial Parasite, Listeria Monocytogenes”, J Cell Biol , 1989, 109, 1597.
Cohen Mark S.
Minnifield Nita
Pearl Cohen Zedek Latzer LLP
The Trustees Of The University Of Pennsylvania
LandOfFree
Methods and compositions for immunotherapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for immunotherapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for immunotherapy of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3625106